Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Ursodeoxycholic Acid. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN104193792B reveals a one-step microwave-assisted conversion of chenodeoxycholic acid. This report analyzes cost reduction in API manufacturing and supply chain reliability for high-purity ursodeoxycholic acid.
Novel enzymatic method for UDCA and TUDCA from pig bile. High purity, scalable process. Reliable pharmaceutical intermediates supplier for cost reduction.
Novel plant-derived synthesis route for Ursodeoxycholic Acid ensures high purity and supply continuity. Ideal for pharmaceutical intermediates manufacturing.
Patent CN102766185A details a novel method for recovering ursodesoxycholic acid and chenodeoxycholic acid from waste mother liquor, offering significant cost reduction and supply chain reliability.
Novel stigmasterol based UDCA preparation method ensures high purity and supply chain stability for pharmaceutical intermediates manufacturing processes.
Patent CN110669091A reveals a novel DIPEA salt crystallization method for high-purity ursodeoxycholic acid, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturers.
Advanced purification process for ursodeoxycholic acid ensures 99.8% purity. Optimized solvent usage reduces energy consumption for reliable pharmaceutical intermediate supply chains.
Advanced P450 enzyme mutant technology enables efficient ursodeoxycholic acid production. Reduces costs and improves supply chain reliability for pharmaceutical intermediates.
Patent CN114539342B reveals an industrial method for TUDCA using alcohol solvents to reduce impurities, offering cost-effective pharma intermediate manufacturing.
Novel esterification-crystallization method removes double oxide impurities, ensuring superior quality for ursodeoxycholic acid production.
Patent CN119506235A reveals directed evolution for UDCA. Enhances supply chain stability and reduces manufacturing costs significantly.
Patent CN112588319A reveals a novel silane-catalyzed route for TUDCA synthesis, offering cost reduction in API manufacturing and enhanced supply chain reliability.
Patent CN102070693A details a high-yield chiral hydrogenation method for ursodeoxycholic acid, offering superior purity and cost-effective manufacturing for global pharmaceutical supply chains.
Patent CN107099516B reveals a stable 7β-hydroxysteroid dehydrogenase mutant enabling high-concentration ursodeoxycholic acid synthesis with superior thermal stability and simplified downstream processing.
Patent CN118745205A details a plant-derived ursodeoxycholic acid synthesis avoiding animal risks. Offers high purity and scalable supply chain solutions.
Patent CN118638174A reveals a plant-based UDCA synthesis route. Achieve 99.91% purity with reduced viral risk and scalable enzymatic steps for reliable supply.
Patent CN119119158A reveals a novel plant-derived route for ursodeoxycholic acid. Achieve high purity and cost reduction in API manufacturing with scalable bio-hybrid synthesis.
Patent CN105294809A reveals a novel two-step synthesis for high-purity Tauroursodeoxycholic Acid, eliminating toxic impurities and ensuring scalable pharmaceutical intermediate manufacturing.
Patent CN108546691B discloses a novel 7β-HSDH mutant utilizing cheap NADH for ursodeoxycholic acid production, offering significant cost reduction and scalable biocatalysis solutions.
Patent CN107099516A details high-efficiency enzymatic UDCA production. This report analyzes cost reduction and supply chain reliability for pharmaceutical manufacturers.